구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Relatlimab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Various Advanced Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel ICI combinations enter routine clinical practice |
Positioning Known limitation | resistance to PD-1 blockade remains a major clinical challenge |
MoA Mechanism | checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting a |
MoA Biomarker | biomarkers and immunotherapeutic targets in skin melanoma, warranting further investigation |
PK/PD Half-life | 26 h |
PK/PD Species | Mouse, PSA, radiologic progression-free survival, and toxicity. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, PSA, radiologic progression-free survival, and toxicity. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia and dermatitis |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia and dermatitis |
Clinical Selected reported efficacy | ORR 71.4% |
Clinical Reported ORR | 92.9% |
Clinical Reported PFS | 20.90 |
Clinical Reported OS | 31.34 |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03310619 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Relatlimab |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Various Advanced Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel ICI combinations enter routine clinical practice |
Positioning Known limitation | resistance to PD-1 blockade remains a major clinical challenge |
MoA Mechanism | checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting a |
MoA Biomarker | biomarkers and immunotherapeutic targets in skin melanoma, warranting further investigation |
PK/PD Half-life | 26 h |
PK/PD Species | Mouse, PSA, radiologic progression-free survival, and toxicity. |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, PSA, radiologic progression-free survival, and toxicity. |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | thrombocytopenia and dermatitis |
Toxicology CRS | Reported |
Clinical Safety signal | thrombocytopenia and dermatitis |
Clinical Selected reported efficacy | ORR 71.4% |
Clinical Reported ORR | 92.9% |
Clinical Reported PFS | 20.90 |
Clinical Reported OS | 31.34 |
Clinical Result source | ClinicalTrials.gov NCT03310619 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03310619 |
추천 비교
추천 비교